NCT05779644

Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 300 (estimated)
• Sponsor: RenJi Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to analyze the effects of GLP-1RA on blood glucose, body weight, glucose and lipid metabolism and fat distribution in overweight/obese patients with type 2 diabetes mellitus.

Detailed description

Specific research contents: To study the characteristics of glucose and lipid metabolism and fat distribution in overweight/obesity patients with type 2 diabetes mellitus; liraglutide/ semaglutide/ metformin will be applied to patients for one year, and the changes of lipid metabolism and fat distribution in overweight/obese patients with type 2 diabetes and the differences among the three groups will be analyzed before and after treatment. The metabolomic changes of overweight/obese patients with type 2 diabetes before and after medication and the differences among the three groups will be analyzed. Explore the correlation between visceral fat content, glucose and lipid metabolism, inflammatory factors and other biochemical indicators and metabolomics.

Conditions

• Metformin
• Obesity, Abdominal
• Diabetes Mellitus, Type 2
• Abdominal Fat
• Non-Alcoholic Fatty Liver Disease
• Metabolism Disorder, Glucose
• Metabolism Disorder, Lipid

Interventions

Type	Name	Description
DRUG	Liraglutide	Liraglutide is injected once a day.
DRUG	Semaglutide	Semaglutide is injected once a week.
DRUG	Metformin	Metformin is taken orally daily.

Timeline

• Start date: 2023-02-23
• Primary completion: 2025-02-23
• Completion: 2025-02-23
• First posted: 2023-03-22
• Last updated: 2023-05-16

Locations

1 site across 1 country: China